Did you know? We engineer the ‘T cell receptor’ to call in existing T cells, and let the body do the rest. #innovation #medicine #oncology #IMCRSharing
Immunocore’s Post
More Relevant Posts
-
Join our panel of experts as they discuss overcoming barriers to better care in #cholangiocarcinoma #CCA #oncology #MedEd #PeerVoice https://lnkd.in/dNRHyXUJ
To view or add a comment, sign in
-
In this video, we can see ovalbumin positive target cells have increased T-cell visits and these cells spend more time interacting with target cells. This is compared to cells without the surface protein which have reduced numbers of both. Livecyte allows us to compare and correlate treatments at a population level. Did you know that population heterogenity can affect your results? 👇 Watch our next video to find out how. #Livecyte #TCells #CancerResearch #Oncology
Deeper insight into effector-target interactions
To view or add a comment, sign in
-
Not all cells act the same! The cell in this video shows very little T-cell interaction and takes a lot longer to reach cell death. Livecyte can monitor these differences per cell and give population metrics based on the number and the time T cells are bound. Learn how Livecyte can quantify population heterogeneity in T cell: target cell interactions 👇 #Cells #Livecyte #Oncology #TCells #CancerResearch
Cell heterogeneity in your population
To view or add a comment, sign in
-
Learn from RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using irRECIST to assess tumor burden. https://lnkd.in/ekZYn6Jx #MedicalImaging #ClinicalTrials #ChooseCalyx #ESMO2023
Improving how we Evaluate Treatment Response in Oncology Research | Learn More at ESMO
To view or add a comment, sign in
-
The identification of genetic alterations in soft tissue sarcoma has led to the rise of targeted therapy, significantly expanding the therapeutic landscape. Remaining up to date on emerging data is crucial. #SarcomaAwarenessMonth #OncologyEducation #Oncology
To view or add a comment, sign in
-
-
Learn from #RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using #irRECIST to assess tumor burden. https://lnkd.in/dDNPSurm #MedicalImaging #ClinicalTrials #ChooseCalyx
To view or add a comment, sign in
-
Learn from RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using irRECIST to assess tumor burden. https://lnkd.in/gRETtG7E #MedicalImaging #ClinicalTrials #ChooseCalyx #ASCO23
To view or add a comment, sign in
-
Learn from #RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using #irRECIST to assess tumor burden. https://lnkd.in/gpsgc4Dy #MedicalImaging #ClinicalTrials #ChooseCalyx
To view or add a comment, sign in
-
Customer Success | Program Manager | Learning Management System Manager | Client Education | Client Communication | Certificate in Digital Marketing
Learn from #RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using #irRECIST to assess tumor burden. https://lnkd.in/gW7dhgH5 #MedicalImaging #ClinicalTrials #ChooseCalyx
To view or add a comment, sign in